Authors
Alexandre Bertucci, Pauline Maby, Anne Sophie Chrétien, Samuel Granjeaud, Chloé Reine, Amira Ben-Amara, Marie-Sarah Rouvière, Laurent Gorvel, Emilien Billon, Brice Chanez, François Legrand, Claire Cropet, Jean-Sébastien Frenel, Christophe Le Tourneau, Alice Hervieu, Elodie Coquan, Thibault de La Motte Rouge, Esma Saada-Bouzid, Pernelle Lavaud, Julién Hédou, Brice Gaudillière, Aaron Lisberg, Renaud Sabatier, Anthony Gonçalves, Daniel Olive, Philippe Rochigneux
Published in
Cancer immunology research. Nov 17, 2026. Epub Nov 17, 2026.
Abstract
To improve ICI efficacy in advanced CC, a promising strategy is to combine anti-PDL-1, anti-CTLA-4 and chemotherapy. The phase I/II MOVIE trial reported a clinical benefit rate of 53.1% of durvalumab, tremelimumab and metronomic oral vinorelbine in patients with pretreated metastatic CC. The objective of this study is to discover immune efficacy biomarkers of this combination. We analyzed 29 advanced CC patients from MOVIE multicentric prospective clinical trial (NCT03518606). We used high-dimensional mass cytometry (CyTOF) to explore the immune landscape in baseline peripheral blood mononuclear cells. We developed 3 immune panels of 40 antibodies (T cells, NK cells and myeloid cells) for the deep-phenotyping of PBMCs. Our bioinformatics workflow of CyTOF data included dimensionality reduction (opt-SNE, UMAP), automated clustering (PhenoGraph) and regression (CITRUS). The biomarker candidates were submitted to a model prediction composed of 11 machine-learning algorithms. In baseline blood samples, high-dimensional analyses consistently identified a population of TOX+TIGIT+CD57+ TEMRA (CD45RA+CCR7-) CD8+ T cells associated with improved clinical outcomes: clinical benefit (CB), progression-free survival (PFS) and overall survival (OS). This population was confirmed by manual gating and 11 machine-learning algorithms. After determining a cut-off at 0.73% of CD45+ cells, patients with an increased blood baseline frequency of TOX+TIGIT+CD57+ TEMRA (CD45RA+CCR7-) CD8+ T cells had an improved CBR (76% vs 25%, p=0.005), an improved PFS (HR=0.35, CI95, 0.13-0.95, p=0.013) and an improved OS (HR=0.19, CI95, 0.07-0.53, p=0.001). Multivariate analysis with classical CC prognostic factors confirmed the OS benefit of our biomarker (HR=0.15, CI95: 0.05-0.47, <0.001).
PMID:
43044083
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 0
- Comments 0